Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
The functioning of US government is facing a systemic crisis
Comparing the UK & US Approaches to First-Line Treatment in Hodgkin Lymphoma
Being well-informed about clinical trials was associated with a greater willingness to participate.
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
An abstract is unavailable.
Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a study published in the Journal of Clinical Investigation.
This special collection on vestibular schwannoma seeks to provide a comprehensive overview of the latest advancements and challenges in the field, featuring …
KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.
The study compared treatment with dual HER2 inhibitors to a standard EGFR inhibitor-based treatment in patients with previously treated, HER2-positive disease. It found that the…
SEN Radio has parted ways with prominent cricket journalist Peter Lalor halfway through Australia’s tour of Sri Lanka over his social media activity relating to…